15:14:52 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-14 Kvartalsrapport 2024-Q3
2024-08-29 Kvartalsrapport 2024-Q2
2024-05-30 Kvartalsrapport 2024-Q1
2024-04-25 Extra Bolagsstämma 2024
2024-04-19 X-dag ordinarie utdelning LYTIX 0.00 NOK
2024-04-18 Årsstämma 2024
2024-02-29 Bokslutskommuniké 2023
2023-11-09 Kvartalsrapport 2023-Q3
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-11 Kvartalsrapport 2023-Q1
2023-04-19 X-dag ordinarie utdelning LYTIX 0.00 NOK
2023-04-18 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-12 Kvartalsrapport 2022-Q1
2022-04-22 X-dag ordinarie utdelning LYTIX 0.00 NOK
2022-04-21 Årsstämma 2022
2022-02-17 Bokslutskommuniké 2021

Beskrivning

LandNorge
ListaEuronext Growth Oslo
SektorHälsovård
IndustriBioteknik
Lytix Biopharma är ett bioteknikbolag i kliniskt stadium som utvecklar nya cancerimmunterapier. Bolagets teknik bygger på forskning inom antimikrobiella peptider, ett försvar riktade mot patogener. Lytix Biopharmas huvudprodukt, LTX-315, är en onkolytisk peptid med syftet att personalisera immunterapi. Bolaget bedriver sin forskning och verksamhet i Oslo, Norge.
2022-08-25 07:59:38
Lytix Biopharma, a Norwegian immune-oncology company, today releases its second
quarter and first half 2022 results - New encouraging clinical data.

"The first six months of 2022 have been fueled by clinical development and
clinical data presentations across international conferences alongside seeing
our partner Verrica Pharmaceuticals advance its Phase II study evaluating
LTX-315 for basal cell carcinoma. For Lytix, the most significant clinical trial
development was the completion of the Phase II study evaluating LTX-315 in
combination with adoptive therapy (ACT) in soft tissue sarcoma patients. This
combination treatment provided meaningful clinical benefit for patients with
progressive metastatic soft tissue sarcoma and clearly shows the potential of
using LTX-315 in combination with ACT to generate a high number of
tumor-specific T cells", says Dr. Øystein Rekdal, CEO of Lytix Biopharma.


Highlights from the first quarter 2022:

o Data from the Phase II ATLAS-IT-04 trial evaluating LTX-315 in sarcoma
patients demonstrated proof-of-concept by showing that the compound improved the
outcome of adoptive cell transfer treatment by stabilizing the disease in
patients with progressive metastatic soft tissue sarcoma.
o In April, Verrica Pharmaceuticals dosed the first patient in its Phase II
study evaluating LTX-315 in basal cell carcinoma (BCC), triggering an initial
milestone payment to Lytix.
o Regulatory process is initiated and ongoing to expand the site network for the
ATLAS-IT-05 study to highly recognized sites with intratumoral immunotherapy
expertise in three European countries.
o The preclinical safety testing for LTX-401 has been completed demonstrating a
favorable safety profile. Preparations for a Phase I clinical study are
progressing according to plan.
o In April, Lytix received a USD 1 million milestone payment from Verrica
following first patient dosed in its Phase II study of LTX-315 for the treatment
of basal cell carcinoma.
o Total operating expenses for the six months ended 30 June 2022 ended at NOK
36.6 million, which is in line with last year's figures of NOK 36.1 million.

Key figures (unaudited):

Profit and loss:

Amounts in 1000 NOK Q2 2022 Q2 2021 H1 2022 H1 2021 FY 2021

Total op. income 10 427 1 640 11 936 23 201 25 827
Total op. expenses (20 418) (14 041) (36 600) (36 054) (73 844)
Loss from operations (9 991) (12 401) (24 664) (12 853) (48 017)
Loss for the period (1 183) (12 392) (16 414) (12 748) (48 049)

Balance sheet:

Amounts in 1000 NOK Q2 2022/2021 H1 2022 H1 2021 FY 2021

Property, plant and equipment - 132 - -
Cash position at the end
of the period - 177 084 70 950 197 282
Trade and other receivables - 6 893 162 792 5 680
Total assets - 184 108 233 742 202,962

Total equity - 173 967 223 030 189,624
Total liabilities - 10 141 10 712 13,338
Total equity and liabilities - 184 108 233 742 202,962

The full report and a presentation are linked to this press release (and
available at https://www.lytixbiopharma.com/investors/financial-reports.html).

The results will be presented in a webcast with CEO Øystein Rekdal, CDO Graeme
Currie and CFO Gjest Breistein at 14:30 CEST.

The presentation and subsequent Q&A session will be held in English and may be
viewed live. Please register for the presentation here:
https://forms.office.com/pages/responsepage.aspx?id=-QEn0CM7P0uPzintVGMr-Gxc6nJw
_YlNh1teJiuU8DNUQkJWMjJQM1hKWTVKQlJLVUE5V000NFdWNi4u&web=1&wdLOR=cCF82F75B-A9EE-
4BBB-B49E-D7CAAB931F59

A recording of the presentation will be made available on
https://www.lytixbiopharma.com/investors/financial-reports.html after the
presentation.


For more information, please contact:
Ole Peter Nordby, ole.peter.nordby@lytixbiopharma.com

Lytix Biopharma in brief:
Based in Oslo, Norway, Lytix is a clinical stage biotech company developing
novel cancer immunotherapies, an area within cancer therapy that is aimed at
activating the patient's immune system to fight cancer. The company's technology
is based on pioneering research in "host defense peptides" - nature's first line
of defense towards foreign pathogens. Lytix Biopharma's lead product, LTX-315,
is a first-in-class oncolytic molecule representing a new and superior
therapeutic principle to boost anti-cancer immunity, with the potential to be
the ideal combination partner with other types of immunotherapies. LTX-315
targets cancer cells and disintegrates their cell membranes, causing immunogenic
cell death and release of a patient's tumor specific antigens and potent
immunostimulants. This mode of action allows cytotoxic T cells to recognize,
infiltrate and attack cancer cells.